Advertisement

HBIO

Harvard Bioscience, Inc.

Healthcare · USD

Set alert

Price alert · HBIO

All alert types
8.90 USD +0.10 +1.14%
As of Oct 30, 2026 Extended hours 8.90 0.00%
Bid
8.86 × 2
Ask
8.90 × 2
8.80 Day range 8.92
4.31 52-week range 8.90
YTD
+32.84%
1 year
+41.27%
Open
8.80
Prev close
8.80
Mkt cap
40.52M
Vol
23.17K
Avg vol
19.26K
EPS
-2.31
P/E
0.00
Div yield
0.00%
More statistics
Low
8.80
High
8.92
Forward P/E
14.00
Beta
1.31
Short ratio
2.66
Inst. own
75.99%
Dividend
0.00
Ex-div date
50-d avg
2.30
200-d avg
3.04
1y target
6.25

5D chart

Chart tools
Interval
HBIO five-day price chart8.108.328.558.789.00Oct 23Oct 26Oct 27Oct 28Oct 29

Key statistics

Market cap
91.59M
Enterprise value
133.38M
Trailing P/E
0.00
Forward P/E
14.00
PEG ratio
0.00
Price / sales
0.94
Price / book
1.40
EPS (TTM)
-0.33
Beta
1.31
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-14.57%
Revenue (TTM)
97.73M
Revenue growth
-13.40%
Free cash flow
6.06M
Total cash
4.57M
Total debt
45.91M
Return on equity
-20.40%
Shares outstanding
43.62M
Short % of float
1.11%
50-day average
2.30
200-day average
3.04

Analyst view

Consensus: none

Price target (mean) 6.25 -29.8% downside
Target (low)
5.50
Target (mean)
6.25
Target (high)
7.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
  • Strong buy0
  • Buy2
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Consensus EPS estimate 0.05.

Earnings history

Financials — quick view

All financials
HBIO Revenue — quarterly 22.73M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
HBIO Net income — quarterly -2.91M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
HBIO EPS — quarterly -0.64
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

HBIO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 7, 2024Sep 1, 20240.05-0.02-0.07-140.00%
Aug 8, 2024Jun 1, 20240.05-0.03-0.08-160.00%
Aug 8, 2024Jun 1, 20240.050.00——
May 7, 2024Mar 1, 20240.020.020.000.00%
May 7, 2024Mar 1, 20240.020.00——
Mar 7, 2024Dec 1, 20230.050.01-0.04-80.00%

Upgrades / downgrades

HBIO analyst upgrades and downgrades
DateFirmActionFromTo
Jun 22, 2023BenchmarkreitSpeculative BuySpeculative Buy
Apr 26, 2023Benchmarkmain—Buy
Apr 26, 2023Keybancmain—Overweight
Mar 10, 2023Benchmarkreit—Buy
Nov 9, 2022Keybancmain—Overweight
Aug 5, 2022Keybancmain—Overweight

About Harvard Bioscience, Inc.

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
United States

News

Your note

Sign in to keep a note on HBIO — it syncs with the Stock Master app.

Insider holders

HBIO insider holders
InsiderRelationLatest transactionDateShares held
COTE JENNIFERChief Financial OfficerStock Award(Grant)Mar 4, 2024168,738
EADE KATHERINE ANNEDirectorStock Award(Grant)May 20, 2024311,126
EDRICK ALAN IANDirectorStock Award(Grant)May 20, 2024273,911
GREEN JAMES WChief Executive OfficerPurchaseJun 12, 20243,111,090
LOEWALD THOMAS WDirectorStock Award(Grant)May 20, 2024295,311
LOY BERTRANDDirectorStock Award(Grant)May 20, 2024556,208

Institution ownership

HBIO institution ownership
Holder% heldSharesValueReported
Blackrock Inc.6.69%2,916,1766.12MSep 29, 2024
Punch & Associates Investment Management, Inc.6.36%2,772,7005.82MSep 29, 2024
Harvey Partners, LLC6.22%2,715,0005.70MSep 29, 2024
AMH Equity Ltd.5.48%2,388,8685.02MSep 29, 2024
Vanguard Group Inc4.94%2,154,0524.52MSep 29, 2024
Granahan Investment Management LLC4.28%1,865,4293.92MSep 29, 2024

Fund ownership

HBIO fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.89%1,261,6932.65MSep 29, 2024
Heartland Value Fund2.75%1,200,0002.52MSep 29, 2024
iShares Russell 2000 ETF2.18%952,1212.00MOct 30, 2024
Royce Micro-Cap Fund1.48%647,0171.36MSep 29, 2024
Vanguard Extended Market Index Fund1.33%579,9861.22MSep 29, 2024
JNL Series Trust-JNL/Multi Manager Small Cap GrowthFd1.04%453,803952.99KSep 29, 2024
Advertisement